Anantharaju Arpitha, Roy Baishali, Deodhare Kirti Girish, Srinivas Bheemanathi Hanuman, Bade Bhavana Ashok, Naik Parvathi
Department of Gynecology, JIPMER, Pondicherry, India.
Department of Pathology, JIPMER, Pondicherry, India.
Indian J Surg Oncol. 2023 Jun;14(2):497-503. doi: 10.1007/s13193-022-01585-9. Epub 2022 Jul 21.
To study the clinical, paraneoplastic hematological presentation of Sertoli Leydig cell tumor patients. This retrospective study involved women with Sertoli Leydig cell tumors treated at JIPMER from 2018 to 2021. We reviewed the hospital registry for the Sertoli Leydig cell tumor among all the ovarian tumors being treated in the department of obstetrics and gynecology. We retrieved the datasheets of patients with Sertoli Leydig cell tumor and studied their clinical and hematological presentation, their management, complications, and follow-up. We had 5 patients of Sertoli Leydig cell tumor of 390 ovarian tumors operated during the study period. The mean age at presentation was 31.6 years. All 5 patients had hirsutism and menstrual irregularity. One patient presented with symptoms of polycythemia along with these complaints. Elevated serum testosterone was seen in all (mean being 688 ng/ml). Mean preoperative hemoglobin was 15.84%, and mean hematocrit was 50.14%. Fertility-sparing surgery was performed in 3 of them and the rest had complete surgery. All patients were in Stage IA. Histologically, one had Pure Leydig cell, three had steroid cell tumor not otherwise specified and one was mixed Sertoli Leydig cell tumor. After the operation, the hematocrit and testosterone levels came down to the normal range. The virilizing manifestations regressed over 4-6 months. With a follow-up period ranging from 1 to 4 years, all 5 patients are alive, one patient had a disease recurrence in the ovary after 1 year of primary surgery. She is disease-free following the second surgery. The rest of the patients had no disease recurrence and are disease-free following surgery. Virilizing ovarian tumors can have paraneoplastic polycythemia which needs to be looked into while evaluating these patients. Similarly, while evaluating polycythemia in young females, an androgen-secreting tumor has to be ruled out as it is reversible and completely treatable.
研究支持间质细胞瘤患者的临床及副肿瘤性血液学表现。这项回顾性研究纳入了2018年至2021年在JIPMER接受治疗的支持间质细胞瘤女性患者。我们查阅了妇产科正在治疗的所有卵巢肿瘤中支持间质细胞瘤的医院登记资料。我们检索了支持间质细胞瘤患者的数据表,并研究了他们的临床和血液学表现、治疗、并发症及随访情况。在研究期间接受手术的390例卵巢肿瘤中,有5例支持间质细胞瘤患者。就诊时的平均年龄为31.6岁。所有5例患者均有多毛症和月经不规律。1例患者在出现这些症状的同时还伴有红细胞增多症症状。所有患者血清睾酮均升高(平均为688 ng/ml)。术前平均血红蛋白为15.84%,平均血细胞比容为50.14%。其中3例患者接受了保留生育功能的手术,其余患者接受了根治性手术。所有患者均处于IA期。组织学上,1例为纯Leydig细胞型,3例为未另行分类的类固醇细胞瘤,1例为混合性支持间质细胞瘤。术后,血细胞比容和睾酮水平降至正常范围。男性化表现4至6个月后消退。随访期为1至4年,所有5例患者均存活,1例患者在初次手术后1年卵巢疾病复发。二次手术后她无病生存。其余患者无疾病复发,术后无病生存。男性化卵巢肿瘤可伴有副肿瘤性红细胞增多症,在评估这些患者时需要考虑到这一点。同样,在评估年轻女性的红细胞增多症时,必须排除分泌雄激素的肿瘤,因为它是可逆的且完全可治疗。